Get started
Author

Ágnes Benedict

The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review
2007 · J. A. Cramer, Á. Benedict, et al. · International Journal of Clinical Practice · 487
Overview of Parametric Survival Analysis for Health-Economic Applications
2013 · K. Jack Ishak, Noemi Kreif, et al. · PharmacoEconomics · 133
Simulation and Matching-Based Approaches for Indirect Comparison of Treatments
2015 · K. Jack Ishak, Irina Proskorovsky, et al. · PharmacoEconomics · 110
The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review
2008 · N. Muszbek, D. Brixner, et al. · International Journal of Clinical Practice · 98
PDF
Treatment costs of prostate cancer in the first year after diagnosis: a short‐term cost of illness study for France, Germany, Italy, Spain and the UK
2009 · Richard Olivier Fourcade, Ágnes Benedict, et al. · British Journal of Urology · 80
Incidence-based Cost-of-illness Model for Metastatic Breast Cancer in the United States
2012 · Sonja V. Sorensen, Jo Wern Goh, et al. · International Journal of Technology Assessment in Health Care · 75
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial
2007 · on behalf of the ATAC Trialists' Group, R Mansel, et al. · British Journal of Cancer · 61
PDF
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making
2020 · Ting-An Tai, Nicholas R. Latimer, et al. · Value in Health · 51
PDF
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective
2016 · Andrzej J. Jakubowiak, Marco Campioni, et al. · Journal of Medical Economics · 51
PDF
Economic evaluation of new targeted therapies for the first‐line treatment of patients with metastatic renal cell carcinoma
2011 · Ágnes Benedict, Robert A. Figlin, et al. · British Journal of Urology · 45
Clinical and Economic Outcomes Associated with Treatment Sequences In Patients With BRAF -Mutant Advanced Melanoma
2018 · Ahmad Tarhini, David McDermott, et al. · Immunotherapy · 35
PDF
Ql4 Patient-rated Utilities in Postmenopausal Early Breast Cancer (ebc):a Cross-country Comparison
2004 · SV Sorensen, R Brown, et al. · Value in Health · 35
PDF
Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data
2010 · M E Stokes, L Black, et al. · Prostate Cancer and Prostatic Diseases · 34
First-year costs of treating prostate cancer: estimates from SEER-Medicare data
2009 · C G Roehrborn, P Albertsen, et al. · Prostate Cancer and Prostatic Diseases · 32
Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland☆
2009 · Ágnes Benedict, Jorge Arellano, et al. · Journal of Affective Disorders · 27
Sequential Treatment Approaches in the Management of BRAF Wild-Type Advanced Melanoma: A Cost–Effectiveness Analysis
2018 · Ahmad Tarhini, Agnes Benedict, et al. · Immunotherapy · 26
PDF
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
2017 · Andrzej J. Jakubowiak, Ivan Houisse, et al. · Expert Review of Hematology · 24
The Cost Effectiveness of Rufinamide in the Treatment of Lennox-Gastaut Syndrome in the UK
2010 · Ágnes Benedict, Lara Verdian, et al. · PharmacoEconomics · 24
Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System
2010 · Michael P. Lux, Achim Wöckel, et al. · Onkologie · 23
PDF
An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK
2009 · Ágnes Benedict, David A. Cameron, et al. · PharmacoEconomics · 23
Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies
2019 · Venediktos Kapetanakis, Thibaud Prawitz, et al. · PharmacoEconomics · 18
Economic evaluation of sunitinib, sorafenib, bevacizumab/interferon-alfa or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma (mRCC): An indirect comparison
2008 · A. Benedict, C. Charbonneau, et al. · Journal of Clinical Oncology · 16
Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia
2009 · Krister Järbrink, Noemi Kreif, et al. · Current Medical Research and Opinion · 11
Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer
2005 · Ágnes Benedict, Ruth E Brown · Expert Opinion on Pharmacotherapy · 10
Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model
2024 · Ágnes Benedict, Gábor Szabó, et al. · Journal of the National Comprehensive Cancer Network · 9
PDF
Works count: 107
Citation count: 1,658
H-index: 20
I10-index: 24
Year
Topic
Type